High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
about
Recent strategies targeting HIV glycans in vaccine designDeconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and ImmunityNeutralization of tier-2 viruses and epitope profiling of plasma antibodies from human immunodeficiency virus type 1 infected donors from IndiaAnti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypesHeterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to the HIV-1 gp41 2F5 neutralization determinant.An optimally constrained V3 peptide is a better immunogen than its linear homolog or HIV-1 gp120Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjectsEnhanced exposure of human immunodeficiency virus type 1 primary isolate neutralization epitopes through binding of CD4 mimetic compounds.Inhibition of in vivo HIV infection in humanized mice by gene therapy of human hematopoietic stem cells with a lentiviral vector encoding a broadly neutralizing anti-HIV antibody.The presence of glutamine at position 315 but not epitope masking predominantly hinders HIV subtype C neutralization by the anti-V3 antibody B4e8.Identifying and characterizing recently transmitted viruses.Magnitude and breadth of a nonprotective neutralizing antibody response in an efficacy trial of a candidate HIV-1 gp120 vaccineFolding domains within the ricin toxin A subunit as targets of protective antibodiesVariations in autologous neutralization and CD4 dependence of b12 resistant HIV-1 clade C env clones obtained at different time points from antiretroviral naïve Indian patients with recent infection.Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodiesVaccine-induced IgG antibodies to V1V2 regions of multiple HIV-1 subtypes correlate with decreased risk of HIV-1 infection.Specificity of the autologous neutralizing antibody responseStructure/Function Studies Involving the V3 Region of the HIV-1 Envelope Delineate Multiple Factors That Affect Neutralization Sensitivity.Induction of immunity to human immunodeficiency virus type-1 by vaccination.Activity of broadly neutralizing antibodies, including PG9, PG16, and VRC01, against recently transmitted subtype B HIV-1 variants from early and late in the epidemicHIV-1-specific antibody responses during acute and chronic HIV-1 infectionStructure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine designBinding antibody responses to the immunogenic regions of viral envelope in HIV-1-infected Indian children.Diverse antibody genetic and recognition properties revealed following HIV-1 envelope glycoprotein immunization.Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape.Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheetDiscrete partitioning of HIV-1 Env forms revealed by viral capture.Antigenic characterization of the human immunodeficiency virus (HIV-1) envelope glycoprotein precursor incorporated into nanodiscs.Breakthrough Virus Neutralization Resistance as a Correlate of Protection in a Nonhuman Primate Heterologous Simian Immunodeficiency Virus Vaccine Challenge Study.Production and characterization of human anti-V3 monoclonal antibodies from the cells of HIV-1 infected Indian donors.Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.Heterogeneity in neutralization sensitivities of viruses comprising the simian immunodeficiency virus SIVsmE660 isolate and vaccine challenge stock.Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds.Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infectionHIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity.Protective versus pathogenic anti-CD4 immunity: insights from the study of natural resistance to HIV infection.HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study.Specific sequences commonly found in the V3 domain of HIV-1 subtype C isolates affect the overall conformation of native Env and induce a neutralization-resistant phenotype independent of V1/V2 masking.Role of human immunodeficiency virus type 1 envelope structure in the induction of broadly neutralizing antibodies.Preventive and therapeutic applications of neutralizing antibodies to Human Immunodeficiency Virus Type 1 (HIV-1).
P2860
Q26823603-DA44CC1D-3BF3-47E0-B899-A81403D02F21Q27654848-60957454-4A76-47FA-AFA8-83A316F9A733Q28483205-231B0191-4B53-452F-8FE6-CE50997CCAC8Q28752503-586F7970-0964-40FF-9E77-AE9FABAD7AB1Q33812812-399DBEE4-E7C0-4616-864D-C75576F10968Q33820645-58944A90-4246-41BF-87A5-BEBF869F2C1DQ33888559-AD0FED32-DFCE-49C1-9E99-B44D3F21341CQ33964006-9CF3C908-4E99-4218-AAA4-0674D1A700C1Q33990484-93EE0A74-A659-41A8-B9C1-C3FEF771BB0DQ34017550-DFE7B6F8-50CA-49AD-BA83-80EDB412986DQ34038460-30F086C5-4DCD-498D-9394-28FF1033F162Q34157802-3C5DB4AC-E3E8-4E59-839C-E759E917D585Q34196491-89E5962B-5CB1-43CC-B2D3-2E704D0A751AQ34203163-98026C80-0C79-4016-94AF-2387DF9EEF3CQ34392963-FFAD0FA0-AB91-4557-99A8-CAB19F275583Q34402934-CBB3A1E1-D313-4F22-AB49-0DDDE3A198ADQ34415389-06D93D38-B5CF-4E4A-AD89-7F37E31105C7Q34499013-6F4D6AA6-B570-4B18-8DF6-DEE2F4CF64E3Q34540645-AFABADC3-2C15-4D43-A5E3-7BDD841E3AACQ35077704-49D84039-F2A0-439B-AFF8-FEAC8426899FQ35096836-A5D5068A-D4A9-40B6-90F3-3F48D0CF1444Q35196671-6C0CB3EF-15A2-4F30-9FCC-37EDB1371CC7Q35604169-E14853CE-79C6-43BD-8935-C26D1FE332FDQ35691113-593CCB9D-3266-49B4-83BE-2256BF9C22ECQ36000736-BF3D79C3-FD3D-4C57-9A21-7EB16AEF5930Q36057328-E470B7AB-4C1E-4FD0-95E3-71A4FAB6B547Q36088254-6D887437-D04D-4EDC-BE38-CF268301284BQ36267348-2744E113-FCDB-4EBF-8249-EE39C7B7367DQ36334371-E5BCFE83-621D-4B8E-8CF7-AC7A27D066C5Q36384117-73D76CDC-268C-4CCB-9D8C-E3F9848FA217Q36715717-E2EB1F3D-E74D-4D34-A6E3-3AE0D817D011Q36827377-00489A48-53A2-4394-9FFB-2C49E4079A45Q36878885-4758B617-EC04-4FAF-BD7E-FE584789647DQ37273158-3F68D78F-AAC1-4E3A-8ACC-7853F15DB174Q37360774-E0B2CF70-9398-4194-A82A-34F912053241Q37460580-72B28D30-E7D3-4DDD-8FA1-8EC4E944DA2DQ37484124-9F5A978A-3733-4A4A-9736-043CD2CE2ECBQ37554149-DAD199D1-0668-4695-9C82-EB9E6824B671Q38046828-D4A0CB20-E505-4EF1-9A96-E4E9236A2610Q38206519-E203C44F-DCE6-4FBA-8ABC-9CDC9AB4B280
P2860
High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
High titer HIV-1 V3-specific a ...... ion and following vaccination.
@en
High titer HIV-1 V3-specific a ...... ion and following vaccination.
@nl
type
label
High titer HIV-1 V3-specific a ...... ion and following vaccination.
@en
High titer HIV-1 V3-specific a ...... ion and following vaccination.
@nl
prefLabel
High titer HIV-1 V3-specific a ...... ion and following vaccination.
@en
High titer HIV-1 V3-specific a ...... ion and following vaccination.
@nl
P2093
P2860
P50
P1433
P1476
High titer HIV-1 V3-specific a ...... ion and following vaccination.
@en
P2093
Abraham Pinter
Aidy Salomon
Julie M Decker
Katie L Davis
Michael C Keefer
P2860
P304
P356
10.1016/J.VIROL.2009.02.022
P407
P50
P577
2009-03-18T00:00:00Z